CA2930203A1 - N-benzyl tryptanthrin derivative, and preparation method and application thereof - Google Patents

N-benzyl tryptanthrin derivative, and preparation method and application thereof Download PDF

Info

Publication number
CA2930203A1
CA2930203A1 CA2930203A CA2930203A CA2930203A1 CA 2930203 A1 CA2930203 A1 CA 2930203A1 CA 2930203 A CA2930203 A CA 2930203A CA 2930203 A CA2930203 A CA 2930203A CA 2930203 A1 CA2930203 A1 CA 2930203A1
Authority
CA
Canada
Prior art keywords
formula
compound
derivative
ido
tryptanthrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2930203A
Other languages
English (en)
French (fr)
Inventor
Qing Yang
Chunxiang KUANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fudan University
Original Assignee
Fudan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fudan University filed Critical Fudan University
Publication of CA2930203A1 publication Critical patent/CA2930203A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2930203A 2013-11-12 2014-11-12 N-benzyl tryptanthrin derivative, and preparation method and application thereof Abandoned CA2930203A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201310560572.0A CN103570727B (zh) 2013-11-12 2013-11-12 一种n-苄基色胺酮衍生物及其制备方法和应用
CN201310560572.0 2013-11-12
PCT/CN2014/090947 WO2015070766A1 (zh) 2013-11-12 2014-11-12 一种n-苄基色胺酮衍生物及其制备方法和应用

Publications (1)

Publication Number Publication Date
CA2930203A1 true CA2930203A1 (en) 2015-05-21

Family

ID=50043506

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2930203A Abandoned CA2930203A1 (en) 2013-11-12 2014-11-12 N-benzyl tryptanthrin derivative, and preparation method and application thereof

Country Status (11)

Country Link
US (1) US10059712B2 (enExample)
EP (1) EP3070089B1 (enExample)
JP (1) JP6629218B2 (enExample)
KR (1) KR20160103986A (enExample)
CN (2) CN103570727B (enExample)
AU (1) AU2014350729B2 (enExample)
CA (1) CA2930203A1 (enExample)
EA (1) EA201690915A1 (enExample)
MX (1) MX2016006217A (enExample)
WO (1) WO2015070766A1 (enExample)
ZA (1) ZA201603889B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
CN103570726B (zh) * 2013-07-15 2016-04-06 上海天慈生物谷生物工程有限公司 N-烷基色胺酮衍生物及其制备方法和应用
CN103570727B (zh) * 2013-11-12 2015-08-19 复旦大学 一种n-苄基色胺酮衍生物及其制备方法和应用
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN104844607B (zh) * 2015-03-26 2018-02-16 玉林师范学院 一种具有抗肿瘤活性的色胺酮溴代衍生物及其合成方法
CN105218476B (zh) * 2015-10-29 2018-03-13 上海天慈生物谷生物工程有限公司 一种治疗肺癌药物的制备方法
CN105330666B (zh) * 2015-11-27 2018-10-30 西北大学 色胺酮衍生物、合成方法及其药用用途
CN106928230B (zh) * 2015-12-30 2021-03-19 苏州如鹰生物医药有限公司 N-芳基、苄基色胺酮及其衍生物在制备hIDO2抑制剂中的用途
CN106928229B (zh) * 2015-12-30 2021-03-19 苏州如鹰生物医药有限公司 色胺酮及其衍生物在制备hIDO2抑制剂中的用途
CN107141292B (zh) * 2016-03-01 2019-02-12 华中师范大学 一种色胺酮类化合物的制备方法
US10669273B2 (en) * 2016-04-05 2020-06-02 Peking University Use of aza-tryptanthrin derivatives as inhibitors of IDO1 and/or TDO
WO2018136437A2 (en) 2017-01-17 2018-07-26 Tesaro, Inc. Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
US11103511B2 (en) 2017-06-05 2021-08-31 Fudan University Substituted indolo[2,1-b]quinazolines as inhibitors of tryptophan dioxygenase and indoleamine 2,3-dioxygenase 1
CN107286165B (zh) * 2017-06-09 2019-07-26 扬州大学 合成色胺酮类化合物的方法
JP7306634B2 (ja) 2017-10-19 2023-07-11 一般社団法人ファルマバレープロジェクト支援機構 Ｉｄｏ／ｔｄｏ阻害剤
EP3823604A4 (en) 2018-07-17 2022-03-16 Board of Regents, The University of Texas System COMPOUNDS AS INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE AND/OR TRYPTOPHANE DIOXYGENASE
CN110734423B (zh) * 2018-07-18 2022-07-08 复旦大学 一类吲哚醌类吲哚胺-2,3-双加氧酶抑制剂及其药用用途
CN111135178A (zh) * 2018-11-02 2020-05-12 苏州如鹰生物医药有限公司 色胺酮衍生物治疗神经系统疾病的用途
CN110041335B (zh) * 2019-04-24 2022-01-07 同济大学 一种提高色胺酮的水溶性的方法、色胺酮衍生物及其制备方法和应用
CN110183454B (zh) * 2019-06-20 2022-01-07 同济大学 一种含1,2,3-三氮唑的色胺酮及其制备方法和应用
CN110294740A (zh) * 2019-06-20 2019-10-01 同济大学 一种n-苄基氨基酸水溶性色胺酮及其制备方法和应用
CN110283192B (zh) * 2019-07-18 2021-08-06 同济大学 一种含硼酸的色胺酮衍生物的制备方法及应用
CN110903449B (zh) * 2019-12-02 2022-09-06 大连理工大学 一种靛红芳烃共聚物、制备方法及应用
CN112724147B (zh) * 2020-12-23 2022-03-15 合肥工业大学 4(3h)-喹唑啉酮类化合物的制备方法
CN112641728A (zh) * 2020-12-27 2021-04-13 陕西中医药大学 一种色胺酮纳米脂质体及其制备方法
CN118766924A (zh) * 2024-07-08 2024-10-15 陕西中医药大学 一种色胺酮在制备抗结肠癌药物中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8915104D0 (en) * 1989-06-30 1989-08-23 Beecham Group Plc Chemical process
DE4114990A1 (de) * 1991-05-08 1992-11-12 Basf Ag Tryptanthrinderivate
US5441955A (en) * 1993-11-19 1995-08-15 Pathogenesis Corporation Indolo[2,1-biquinazoline-6,12-dione antibacterial compounds and methods of use thereof
JP3272189B2 (ja) * 1994-10-18 2002-04-08 京セラミタ株式会社 ナフチレンジアミン誘導体とそれを用いた電子写真感光体
CA2317711A1 (en) 1998-09-30 2000-04-06 Wrair Indolo[2,1-b]quinazole-6,12-dione antimalarial compounds and methods of treating malaria therewith
WO2000061159A1 (de) * 1999-04-14 2000-10-19 Max Zeller Söhne Ag ARZNEIMITTEL ZUR HEMMUNG VON NF-λB
WO2004064759A2 (en) 2003-01-21 2004-08-05 Chiron Corporation Use of tryptanthrin compounds for immune potentiation
DK1879573T3 (da) 2005-05-10 2013-02-25 Incyte Corp Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
GB0516570D0 (en) * 2005-08-12 2005-09-21 Astrazeneca Ab Amide derivatives
CN101843618A (zh) * 2010-02-26 2010-09-29 复旦大学 小檗碱及其衍生物在制备吲哚胺2,3-双加氧酶抑制剂中的用途
CN102579452B (zh) 2012-01-20 2014-05-14 辽宁思百得医药科技有限公司 色胺酮类化合物在制备ido抑制剂中的用途
CN102532144B (zh) * 2012-01-20 2014-09-10 辽宁思百得医药科技有限公司 一种新型吲哚胺-2,3-双加氧酶抑制剂及其制备方法和用途
US20130281397A1 (en) * 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
CN103054870A (zh) 2013-01-08 2013-04-24 复旦大学 色胺酮类化合物作为吲哚胺2,3-双加氧酶抑制剂的用途
CA2902174A1 (en) 2013-03-14 2014-10-02 Newlink Genetics Corporation Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
CN105517999B (zh) 2013-07-11 2019-06-28 百时美施贵宝公司 Ido抑制剂
CN103570726B (zh) 2013-07-15 2016-04-06 上海天慈生物谷生物工程有限公司 N-烷基色胺酮衍生物及其制备方法和应用
CN103570727B (zh) 2013-11-12 2015-08-19 复旦大学 一种n-苄基色胺酮衍生物及其制备方法和应用
EP3082802B1 (en) 2013-12-03 2020-02-26 Iomet Pharma Ltd. Tryptophan-2,3-dioxygenase (tdo) and/or indolamine-2,3-dioxygenase (ido) inhibitors and their use
GB201322673D0 (en) 2013-12-20 2014-02-05 Tpp Global Dev Ltd Screening method
US9758505B2 (en) 2014-02-12 2017-09-12 Iteos Therapeutics 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use

Also Published As

Publication number Publication date
MX2016006217A (es) 2017-02-23
AU2014350729A1 (en) 2016-06-16
AU2014350729B2 (en) 2019-01-03
US20160297822A1 (en) 2016-10-13
CN105829312B (zh) 2018-09-28
WO2015070766A1 (zh) 2015-05-21
CN103570727B (zh) 2015-08-19
EP3070089A1 (en) 2016-09-21
EP3070089A4 (en) 2017-04-26
US10059712B2 (en) 2018-08-28
CN105829312A (zh) 2016-08-03
JP2016535788A (ja) 2016-11-17
EA201690915A1 (ru) 2017-02-28
JP6629218B2 (ja) 2020-01-15
KR20160103986A (ko) 2016-09-02
CN103570727A (zh) 2014-02-12
ZA201603889B (en) 2019-09-25
EP3070089B1 (en) 2019-10-16

Similar Documents

Publication Publication Date Title
AU2014350729B2 (en) N-benzyl tryptanthrin derivative, and preparation method and application thereof
JP2016535788A5 (enExample)
CN102532144B (zh) 一种新型吲哚胺-2,3-双加氧酶抑制剂及其制备方法和用途
EP3495354A1 (en) Ido1 inhibitor and preparation method and application thereof
BR112015017963A2 (pt) composto de fenil amino pirimidina deuterado, método para preparar a composição farmacêutica, composição farmacêutica e uso do composto
JP2020512399A (ja) Ｉｄｏを抑制する化合物、その調製方法及びその使用
CN109678884A (zh) 双-氟喹诺酮噻二唑脲类n-甲基环丙沙星衍生物的制备和应用
CN109400632B (zh) 一种含n-甲基依诺沙星的双-氟喹诺酮基噁二唑脲类衍生物及其制备方法和应用
CN116444517B (zh) 一种羧酰胺类化合物及其在制备去泛素化酶usp28抑制剂中的应用
CN109369676B (zh) 一种双-氟喹诺酮噁二唑脲类n-乙酰诺氟沙星衍生物及其制备方法和应用
JP7034430B2 (ja) 重水素化インドールアミン２，３－ジオキシゲナーゼ阻害剤及びその使用
CN102731525A (zh) 苯并吗啉衍生物
CN109438347B (zh) 一种氰基喹啉类ido1抑制剂、其制备方法及应用
CN109081818A (zh) 新型吲哚胺2,3-双加氧化酶抑制剂
CN116924987B (zh) 4-哌嗪硫脲苯磺酰胺-1,8-萘酰亚胺衍生物及其制备方法和应用
CN103936752A (zh) 靛红类组蛋白去乙酰化酶抑制剂及其制备方法和应用
CN109438482B (zh) 一种含芦氟沙星的双-氟喹诺酮基噁二唑脲类衍生物及其制备方法和应用
CN109369677B (zh) 一种双-氟喹诺酮噁二唑脲类n-甲基环丙沙星衍生物及其制备方法和应用
CN109369675B (zh) 一种双-氟喹诺酮噁二唑脲类培氟沙星衍生物及其制备方法和应用
CN109369674B (zh) 一种含左氧氟沙星的双-氟喹诺酮基噁二唑脲类衍生物及其制备方法和应用
CN109705117A (zh) 三环类化合物、其制备方法及用途
CN109438472B (zh) 一种含n-甲基加替沙星的双-氟喹诺酮基噁二唑脲类衍生物及其制备方法和应用
CN109438481B (zh) 一种含n-甲基莫西沙星的双-氟喹诺酮基噁二唑脲类衍生物及其制备方法和应用
CN109400631B (zh) 一种双-氟喹诺酮噁二唑脲类氧氟沙星衍生物及其制备方法和应用
CN109400627B (zh) 一种含n-甲基洛美沙星的双-氟喹诺酮基噁二唑脲类衍生物及其制备方法和应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191112

FZDE Discontinued

Effective date: 20210831